PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Daver, N. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Jabbour, E. [1 ]
Borthakur, G. [1 ]
Pierce, S. [1 ]
Vaughan, K. [1 ]
Vaughan, K. [1 ]
Ning, J. [2 ]
Gonzalez, G. [2 ]
Pemmarjau, N. [1 ]
Kadia, T. [1 ]
Konopleva, M. [1 ]
Andreeff, M. [1 ]
DiNardo, C. [1 ]
Cortes, J. [1 ]
Ward, R. [3 ]
Craig, A. [3 ]
Ravandi, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Sunesis Inc, San Francisco, CA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S505
引用
收藏
页码：187 / 188
页数：2
相关论文
共 50 条
  • [41] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Verstovsek, S
    Cortes, J
    Ravandi-Kashani, F
    Beran, M
    Garcia-Manero, G
    Koller, C
    O'Brien, S
    Ferrajoli, A
    Estrov, Z
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 250A - 250A
  • [42] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 784A - 784A
  • [43] Farnesyl transferase inhibitor (Tipifarnib, zarnestra; z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabime (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Alvarez, Ricardo H.
    Kantarijan, Hagop
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi-Kashani, Farhad
    Verstovsek, Srdan
    Giles, Francis
    O'Brien, Susan
    Koller, Charles Asa
    Faderl, Stefan
    Thomas, Deborah
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 565A - 566A
  • [44] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Amanda F. Cashen
    Ajit K. Shah
    Laura Todt
    Nicholas Fisher
    John DiPersio
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 759 - 766
  • [45] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Cashen, Amanda F.
    Shah, Ajit K.
    Todt, Laura
    Fisher, Nicholas
    DiPersio, John
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 759 - 766
  • [46] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [47] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [48] Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    McCurdy, Shannon R.
    Gier, Shannon H.
    Babushok, Daria V.
    Frey, Noelle V.
    Gill, Saar I.
    Hexner, Elizabeth O.
    Loren, Alison W.
    Mangan, James K.
    Martin, Mary Ellen
    Perl, Alexander E.
    Maillard, Ivan
    Pratz, Keith W.
    Porter, David L.
    Carroll, Martin P.
    Gimotty, Phyllis A.
    Luger, Selina M.
    BLOOD, 2019, 134
  • [49] Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)
    Pohlen, Michele
    Groth, Christoph
    Sauer, Tim
    Goerlich, Dennis
    Mesters, Rolf
    Schliemann, Christoph
    Lenz, Georg
    Mueller-Tidow, Carsten
    Buechner, Thomas
    Berdel, Wolfgang E.
    Stelljes, Matthias
    BLOOD, 2015, 126 (23)
  • [50] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
12345